David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679.
J Clin Lipidol. 2007 May;1(2):142-7. doi: 10.1016/j.jacl.2007.03.002.
Over the past decade evidence has accumulated that suggests that the anti-inflammatory properties of HDL may be at least as important as the levels of HDL-cholesterol. The recent failure of the torcetrapib clinical trails has highlighted the potential differences between HDL-cholesterol levels and HDL function. Agents to improve HDL function including HDL anti-inflammatory properties provide a new therapeutic strategy for ameliorating atherosclerosis and other chronic inflammatory conditions related to dyslipidemia. Seeking guidance from the structure of the apolipoproteins of the plasma lipoproteins has allowed the creation of a series of polypeptides that have interesting functionality with therapeutic implications. In animal models of atherosclerosis, peptide mimetics of apolipoproteins have been shown to improve the anti-inflammatory properties of HDL, significantly reduce lesions and improve vascular inflammation and function without necessarily altering HDL-cholesterol levels. Some of these are now entering the clinical arena as interventions in pharmacologic and pharmacodynamic studies.
在过去的十年中，有越来越多的证据表明，高密度脂蛋白（HDL）的抗炎特性至少与 HDL-胆固醇水平同样重要。最近 torcetrapib 临床试验的失败凸显了 HDL-胆固醇水平与 HDL 功能之间的潜在差异。改善 HDL 功能的药物，包括 HDL 的抗炎特性，为改善动脉粥样硬化和其他与血脂异常相关的慢性炎症性疾病提供了新的治疗策略。从血浆脂蛋白的载脂蛋白结构中寻求指导，使得能够创造出一系列具有治疗意义的有趣功能的多肽。在动脉粥样硬化的动物模型中，载脂蛋白的肽模拟物已被证明可以改善 HDL 的抗炎特性，显著减少病变，改善血管炎症和功能，而不必改变 HDL-胆固醇水平。其中一些现在作为药理学和药效学研究的干预措施进入临床领域。
